Articles On Arc Exploration (ASX:ARX)

Aroa Biosurgery focuses on transitioning operations to cashflow positive in FY25 US distribution partner TELA Bio reports strong growth to flow through to Aroa Biotech making strong progress on clinical trials and new product lines Soft...

The ASX200 has ended Friday down 0.15pc, but ends week higher Property and Healthcare gains offset by Resources losses  Small Caps led by Gold50   Wall Street hit more record highs on Thursday in New York, the Australian market on Friday,...

Stockhead’s Ashtyn Hiron sits down with AROA Biosurgery (ASX:ARX) CEO Dr. Brian Ward to get the short end of the long story on the company’s latest news. Aroa Biosurgery’s Enivo system may reduce secondary complications in mastectomies, wit...

ASX health sector up in line with broader market but some names ail after quarterly results Cochlear lifts net profit guidance for FY24 after stronger than expected first half sales revenue  CSL to report half year results next week with b...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

AROA reports 80% increase in sales of high-margin Myriad in H1 FY24 TELA Bio’s sales of OviTex and OviTex PRS increase 37% during H1 FY24 on pcp Full-year FY24 guidance has been updated   Special Report: Aroa Biosurgery released strong...

Morgans releases its ASX wound care report seeing value in Aroa Biosurgery, Avita Medical and PolyNovo Global wound care market is estimated to grow at a CAGR of 5.9% to reach US$28.6 billion by 2028 ASX wound care companies head towards p...

Aroa Biosurgery maintains product revenue guidance for FY24, up 25-30% on FY23 Company’s US commercial operations perform particularly well during Q2 FY24 Myriad sales increase to 67% of company’s direct sales mix in Q2 from 50% in Q2 FY23...

ASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports record quarterly sales orders for Q1 FY24 Aroa maintains FY24 revenue growth forecast at 30% after strong Q2 Healthcare and life sciences exp...

Aroa Biosurgery forecasts business growth of up to 30% annually with product revenue guidance of NZ$73-$76 million in FY24 New study highlights positive outcomes using Myriad Matrix and Myriad Morcells in complex traumatic wounds Aroa focu...

ASX health sector falls in line with broader markets on macroeconomic factors and global geopolitical tensions Health imaging stock Volpara announces fourth consecutive quarter of operating cashflow Several ASX healthcare names with positi...

ASX health sector fall in line with broader markets as macroeconomic factors create uncertainty Clinuvel down as its European label expansion of SCENESSE knocked back pending further data 2023 biotech market darling elevated to the S&P...

ASX health stocks fall 1.82% in the past five days in line as broader markets rise slightly Resmed sinks after delivering a mixed quarterly result including margins contracting Weight loss drug frenzy drives global big pharma plays Nova No...

ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product  ImpediMed falls after calls for board spill with discontent following cap raise Healthcare...

ASX health stocks up 1% in the past five days in line with broader markets Volpara records third quarter of positive cashflow following successful growth strategy Gut health a popular theme at 17th Bioshares Biotech Summit along with immun...

ASX health stocks outperforming the broader market but remain flattish for week Several ASX health plays undertaking capital raising with more expected in H2 CY23 Micro-X successfully tests its Argus bomb detection unit opening door to US$...

The S&P/ASX 200 Index (ASX: XJO) is having a tough time on Tuesday. In afternoon trade, the benchmark index is down 1.4% to 7,110.3 points. Four ASX shares that are falling more than most today are listed below. Here’s why they are...

Biotech Aroa has released its audited results for the 2023 financial year, hitting targets and achieving its expectations. The company looks ahead with a positive perspective on FY24, with the group providing new guidance today. The post A...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

ASX health stocks have fallen in the past five days in line with broader markets Volpara Health Technologies reports strong FY23 results, above Morgan’s expectations Pharmaxis reports positive trial results in potential breakthrough treatm...

There could be big returns lurking at the small end of town according to analysts at Morgans. Here’s what it is expecting from these small cap ASX healthcare shares: Aroa Biosurgery Ltd (ASX: ARX) The first small cap ASX healthcare share...

Pharmaxis widens clinical trial following FDA guidance Aroa receives US FDA 510K clearance Cynata gets Australian Ethics approval to commence Phase 2   Pharmaxis to widen Phase 2 trial after FDA feedback Fibrotic diseases specialist Pharm...

ASX health stocks rise 0.97% in the past five days in line with broader markets Impedimed up 99% after BIS tech named in latest US NCCN guidelines for lymphoedema  EBR Systems to release top line results at cardiac conference Heart Rhythm...

The health sector is seen by many experts as one that could remain resilient through times of economic distress. After all, people may cut out dining out or buying a new sofa, but they will still want to remain physically and mentally wel...

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

ASX health stocks fall 1.75% for the past five days Several companies announce successful capital raises Healius drops 15% in the past five days as H1 FY23 results disappoint Healthcare and life sciences expert Scott Power, who has been a...

The All Ordinaries Index (ASX: XAO) is back in the green on Wednesday, driven higher by four shares leaping to new 52-week highs. Right now, the All Ordinaries Index is up 0.12%, trading at 7,606.9 points. Let’s take a closer look at fou...

The All Ordinaries Index (ASX: XAO) is wobbling in and out of the green on Tuesday, but its volatility hasn’t proven enough to stop five shares that call the index home from posting brand new 52-week highs. Indeed, some gained as much as 9...

Tuesday is shaping up to be rough one for many All Ordinaries Index (ASX: XAO) shares. Fortunately, though, not all companies that call the index home are suffering. Indeed, two are soaring into the green to crack new 52-week highs. Right...

Analysts at Wilsons have put the spotlight on one All Ordinaries Index (ASX: XAO) share it prefers over the Polynovo Ltd (ASX: PNV) share price. Polynovo shares fell 3.23% today to $1.98. For perspective, the All Ordinaries Index climbed...

The S&P/ASX 200 Index (ASX: XJO) has faded in afternoon trade but remains on course to record a decent gain. At the time of writing, the benchmark index is up 0.4% to 6,804.5 points. Four ASX shares that are climbing more than most to...

It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings lodgements.  Several small caps from Tech and Healthcare released their reports today, showing that they’re still thriving despite...

Franklin Templeton says innovation accelerates despite recessions, pandemic, wars Expect advancements in sectors like gene therapy and augmented reality in healthcare New ways to grab our attention are reinventing the media industry Frank...

While there are many successful companies on the ASX that solely serve Australian consumers, there are huge markets to be conquered beyond the seas that girt this land. Expanding internationally is difficult to execute but the end result o...

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares leading brokers have named as buys t...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

Dark clouds continue to hover over ASX health stocks Health imaging company Volpara’s FY22 results in line with expectations Fight for fertility company Virtus enters another round Healthcare and life sciences expert Scott Power – a senio...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

With COVID-19 Omicron surging around the globe, ASX healthcare shares are back in the spotlight. While most don’t deal with the pandemic directly, there are many health and biotechnology companies on the ASX that are plugging away quietly...

After a difficult 2021, the Polynovo Ltd (ASX: PNV) share price has bounced 13% this morning after the company provided a trading update. It’s the first notable public communication from the company since the resignation of its long-time se...

There aren’t too many ASX shares that can lay claim to a 10 bagger return in less than 2 years, and there are even fewer fund managers that can say they picked one. However, that’s exactly what Firetrail Investments fund manager, Eleanor S...

It was a mixed bag of results for ASX healthcare shares as we walked through October, as some names came in red hot, whilst others missed the mark completely. After a sharp downturn in late September, where it lost around 7% in just one w...

After a positive start the ASX finished down over 0.5%. Today, APRA ordered the big banks to increase the home loan “serviceability buffer” from 2.5% to 3% from the end of October and hinted more regulation could be forthcoming. Also hittin...

The Aroa Biosurgery Ltd (ASX: ARX) share price is climbing in early trade this morning as the company released its preliminary half-year results. At the time of writing, the surgical technology company’s share price is up 14.81% from the...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which rose by 0.35%. Medical imaging specialist, EMVision (ASX:EMV), has rocketed by 16% after announcing that 1st Gen portable brain scanner has...

Earlier this week the Pinnacle Investment Summit was held and a number of ASX fund managers outlined the stocks they backed. One was Marcus Burns from Spheria Asset Management and he backed one of the ASX’s newest retailers.   Universal Sto...

The cavalcade of life science initial public offers (IPOs) and ASX listings shows few signs of receding, with BCAL Diagnostics (ASX:BDX) last week braving the bourse amid choppy global market conditions. In the life sciences IPO Olympiad, w...